Celgene Corporation (CELG) : Lateef Investment Management reduced its stake in Celgene Corporation by 6.57% during the most recent quarter end. The investment management company now holds a total of 1,846,426 shares of Celgene Corporation which is valued at $209,366,244 after selling 129,737 shares in Celgene Corporation , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Celgene Corporation makes up approximately 6.09% of Lateef Investment Management’s portfolio.
Other Hedge Funds, Including , J.p. Marvel Investment Advisors reduced its stake in CELG by selling 222 shares or 0.36% in the most recent quarter. The Hedge Fund company now holds 61,550 shares of CELG which is valued at $6,979,155. Celgene Corporation makes up approx 2.34% of J.p. Marvel Investment Advisors’s portfolio.Sheaff Brock Investment Advisors reduced its stake in CELG by selling 100 shares or 0.23% in the most recent quarter. The Hedge Fund company now holds 43,095 shares of CELG which is valued at $4,978,765. Celgene Corporation makes up approx 0.61% of Sheaff Brock Investment Advisors’s portfolio.Essex Financial Services reduced its stake in CELG by selling 966 shares or 3.64% in the most recent quarter. The Hedge Fund company now holds 25,597 shares of CELG which is valued at $2,871,727. Celgene Corporation makes up approx 0.68% of Essex Financial Services’s portfolio.Atwood Palmer Inc boosted its stake in CELG in the latest quarter, The investment management firm added 2,543 additional shares and now holds a total of 156,343 shares of Celgene Corporation which is valued at $16,809,999. Celgene Corporation makes up approx 2.92% of Atwood Palmer Inc’s portfolio.Millie Capital Management boosted its stake in CELG in the latest quarter, The investment management firm added 105 additional shares and now holds a total of 12,320 shares of Celgene Corporation which is valued at $1,324,646. Celgene Corporation makes up approx 1.37% of Millie Capital Management’s portfolio.
Celgene Corporation closed down -0.37 points or -0.35% at $106.37 with 34,87,171 shares getting traded on Thursday. Post opening the session at $107.04, the shares hit an intraday low of $105.38 and an intraday high of $107.3025 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.
Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.